Live Analyst Rating Changes 24955 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Roger Song
JEF

Roger Song

Jefferies
Wall Street Analyst
★★☆☆☆
#2404
on 13Foresight · ranked by our own returns
49%
Success Rate
+30.2%
Average Return
30 of 61 calls profitable · +18.1% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 49% of Roger Song's ratings turned a profit when each position was held for 1 year — averaging +30.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

67 Buy 2 Hold 0 Sell
Roger's Stock Coverage 49 ratings · 2026-08-14
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
AVLN
Avalyn Pharma Inc
 Aug 13, 2026 BUY Strong Buy
+45.8% avg upside
3 analysts
$52.00
42.19% Upside
 +7.3% ·
INO
Inovio Pharmaceuticals
 Aug 12, 2026 BUY Buy
+866.1% avg upside
19 analysts
$3.00
233.28% Upside
 +41.6% ·
ORKA
Oruka Therapeutics
 Aug 11, 2026 BUY Strong Buy
+16.8% avg upside
16 analysts
$133.00
22.95% Upside
 +0.0% ·
BIOA
BioAge Labs, Inc.
 Jul 31, 2026 BUY Strong Buy
+241.1% avg upside
9 analysts
$21.00
101.41% Upside
 +17.3% ·
VKTX
Viking Therapeutics
 Jul 30, 2026 BUY Strong Buy
+117.8% avg upside
31 analysts
$101.00
206.69% Upside
 +0.2% ·
MANE
Veradermics, Incorporated
 Jul 16, 2026 BUY Strong Buy
+38.3% avg upside
7 analysts
$182.00
64.04% Upside
 +6.5% ·
TGTX
TG Therapeutics
 Jul 14, 2026 BUY Strong Buy
-7.3% avg upside
20 analysts
$83.00
73.05% Upside
 -11.2% ·
KRYS
Krystal Biotech
 Jul 13, 2026 BUY Strong Buy
-21.7% avg upside
19 analysts
$474.00
44.32% Upside
 -8.6% ·
UTHR
United Therapeutics
 Jul 10, 2026 BUY Buy
-14.2% avg upside
26 analysts
$714.00
42.39% Upside
 -8.6% ·
NRIX
Nurix Therapeutics
 Jul 08, 2026 BUY Strong Buy
+19.2% avg upside
28 analysts
$45.00
65.47% Upside
 +11.3% ·
KLRA
Kailera Therapeutics, Inc.
 Jul 08, 2026 BUY Strong Buy
+150.4% avg upside
5 analysts
$48.00
167.15% Upside
 -17.6% ·
SABS
SAB Biotherapeutics
 May 20, 2026 BUY Strong Buy
+183.9% avg upside
14 analysts
$11.00
193.40% Upside
 +0.5% ·
FATE
Fate Therapeutics
 May 19, 2026 BUY Buy
+373.1% avg upside
31 analysts
$4.00
58.80% Upside
 +36.0% ·
KNSA
Kiniksa Pharmaceuticals
 Apr 28, 2026 BUY Strong Buy
-0.9% avg upside
11 analysts
$71.00
8.77% Downside
 +42.5% ·
ALLO
Allogene Therapeutics
 Apr 15, 2026 BUY Strong Buy
+667.0% avg upside
28 analysts
$10.00
405.09% Upside
 -5.5% ·
REPL
Replimune Group
 Apr 12, 2026 HOLD Strong Buy
+50.5% avg upside
14 analysts
$2.00
86.75% Downside
 +780.6% ·
WVE
Wave Life Sciences
 Mar 26, 2026 BUY Strong Buy
+302.8% avg upside
28 analysts
$18.00
246.10% Upside
 -12.7% ·
CABA
Cabaletta Bio
 Mar 23, 2026 BUY Strong Buy
+413.0% avg upside
16 analysts
$14.00
416.70% Upside
 -2.5% ·
CTMX
CytomX Therapeutics
 Mar 18, 2026 BUY Strong Buy
+222.3% avg upside
21 analysts
$16.00
377.55% Upside
 -23.6% ·
GPCR
Structure Therapeutics, Inc. Sponsored ADR
 Feb 27, 2026 BUY Strong Buy
+89.6% avg upside
17 analysts
$125.00
128.57% Upside
 -13.5% ·
CRVS
Corvus Pharmaceuticals
 Jan 22, 2026 BUY Strong Buy
+68.8% avg upside
14 analysts
$42.00
177.41% Upside
 -41.6% ·
IRON
Disc Medicine
 Dec 19, 2025 BUY Strong Buy
+8.9% avg upside
21 analysts
$154.00
92.38% Upside
 -1.5% ·
NKTR
Nektar Therapeutics
 Dec 17, 2025 BUY Buy
-1.3% avg upside
26 analysts
$121.00
59.31% Upside
 +67.4% ·
KURA
Kura Oncology
 Dec 10, 2025 BUY Strong Buy
+156.5% avg upside
26 analysts
$28.00
177.48% Upside
 +1.1% ·
GYRE
Gyre Therapeutics
 Oct 10, 2025 BUY Strong Buy
+214.9% avg upside
15 analysts
$16.00
144.63% Upside
 -16.7% ·
STRO
Sutro Biopharma
 Sep 09, 2025 BUY Strong Buy
+93.1% avg upside
21 analysts
$40.00
87.72% Upside
 +111.1% ·
BMEA
Biomea Fusion
 Aug 28, 2025 BUY Strong Buy
+934.7% avg upside
15 analysts
$5.00
290.55% Upside
 -33.3% ·
ATYR
aTyr Pharma
 Aug 22, 2025 BUY Buy
+1400.6% avg upside
17 analysts
$17.00
2974.20% Upside
 -89.2% ·
EQ
Equillium
 Aug 20, 2025 BUY Strong Buy
+365.2% avg upside
16 analysts
$4.00
98.95% Upside
 +107.0% ·
MBX
MBX Biosciences, Inc.
 Aug 15, 2025 BUY Strong Buy
+17.9% avg upside
14 analysts
$36.00
46.32% Downside
 +365.8% ·
ALT
Altimmune
 Jun 26, 2025 BUY Strong Buy
+825.3% avg upside
20 analysts
$28.00
872.22% Upside
 -21.9% ·
VXRT
Vaxart
 Jun 11, 2025 BUY Strong Buy
+1293.0% avg upside
8 analysts
$8.00
1328.61% Upside
 +14.0% ·
ACRS
Aclaris Therapeutics
 Apr 24, 2025 BUY Strong Buy
+70.1% avg upside
15 analysts
$7.00
19.52% Upside
 +238.6% ·
PTGX
Protagonist Therapeutics
 Apr 10, 2025 BUY Strong Buy
-23.0% avg upside
19 analysts
$68.00
55.01% Downside
 +141.7% ·
AKBA
Akebia Therapeutics
 Apr 01, 2025 BUY Strong Buy
+978.8% avg upside
16 analysts
$6.00
589.88% Upside
 -26.2% ·
PCVX
Vaxcyte
 Mar 31, 2025 BUY Strong Buy
+76.9% avg upside
15 analysts
$146.00
148.06% Upside
 +53.9% ·
ACRV
Acrivon Therapeutics, Inc.
 Mar 26, 2025 BUY Strong Buy
+685.5% avg upside
13 analysts
$18.00
873.03% Upside
 -45.6% ·
SANA
Sana Biotechnology
 Mar 14, 2025 BUY Strong Buy
+169.8% avg upside
14 analysts
$7.00
90.71% Upside
 +14.7% ·
IOBTQ
IO Biotech
 Jan 27, 2025 BUY Buy
+471499900.0% avg upside
6 analysts
$8.00
799999900.07% Upside
 · ·
ZBIO
Zenas BioPharma, Inc.
 Jan 10, 2025 BUY Strong Buy
+44.3% avg upside
11 analysts
$35.00
19.93% Upside
 +98.0% ·
NVAX
Novavax
 Oct 16, 2024 BUY Hold
+186.4% avg upside
20 analysts
$25.00
207.10% Upside
 -16.4% ·
WHWK
Whitehawk Therapeutics
 Aug 21, 2024 HOLD Buy
+166.3% avg upside
14 analysts
$1.50
67.94% Downside
 +6.5% ·
CBIO
Crescent Biopharma
 Mar 27, 2024 BUY Strong Buy
+33.8% avg upside
17 analysts
$3.00
81.91% Downside
 -92.5% ·
CLDX
Celldex
 Nov 05, 2023 BUY Strong Buy
-4.3% avg upside
28 analysts
$68.00
59.60% Upside
 -13.4% ·
VAXX
Vaxxinity Inc
 Jan 12, 2023 BUY Buy
+10999900.0% avg upside
4 analysts
$15.00
14999900.01% Upside
 · ·
PRLD
Prelude Therapeutics
 Jul 29, 2022 BUY Buy
+102.8% avg upside
7 analysts
$9.00
67.95% Upside
 -20.4% ·
PVLA
Palvella Therapeutics
 May 18, 2021 BUY Strong Buy
+7.7% avg upside
27 analysts
$6.00
96.18% Downside
 -9.4% ·
TVRD
Tvardi Therapeutics
 Apr 29, 2021 BUY Buy
+926.8% avg upside
23 analysts
$23.00
1199.40% Upside
 · ·
FNCHQ
Finch Therapeutics Group
 Apr 13, 2021 BUY Strong Buy
+144.2% avg upside
3 analysts
$29.00
187.10% Upside
 · ·
🔒 44 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Roger Song — Frequently Asked Questions
How accurate are Roger Song's stock ratings?
Based on the calls 13Foresight could measure, about 48% of Roger's ratings were profitable over a one-year hold, with an average return of +30.5% per rating, or +18.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Roger ranked on 13Foresight?
Roger Song is currently ranked #2404 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Roger cover?
Roger most recently has ratings on AVLN, INO, ORKA, BIOA, VKTX, MANE, TGTX, KRYS, UTHR, NRIX, KLRA, SABS and 37 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.